Neobe Therapeutics raises $6.8m seed round for solid-tumour treatment research
ARC Ventures led the financing, which will advance Neobe’s lead programme through preclinical work toward an IND filing targeted for 2028.
Neobe Therapeutics has raised $6.8 million in seed funding led by ARC Ventures. Faber, Macmillan Ventures, Proven Connect and Empirical Ventures participated, alongside returning investor 2048 Ventures.
The UK company is developing engineered bacteria intended to break down physical barriers around solid tumours, allowing immune cells and other cancer treatments to reach them. The funding will support preclinical development of its lead programme, NEO22, toward an IND filing targeted for 2028.
Neobe also plans to strengthen its leadership team as it prepares for clinical development. The new round brings its total funding to more than $10.5 million.
Use of funds
Preclinical development of NEO22
IND filing targeted for 2028
Leadership team expansion